What is Leerink Partnrs’ Forecast for ARCT FY2024 Earnings?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Leerink Partnrs increased their FY2024 EPS estimates for Arcturus Therapeutics in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo now forecasts that the biotechnology company will post earnings per share of ($2.55) for the year, up from their prior estimate of ($3.00). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.80) EPS and Q4 2025 earnings at ($0.79) EPS.

A number of other research analysts have also recently commented on ARCT. HC Wainwright restated a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $66.75.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $17.12 on Friday. The firm has a 50-day simple moving average of $17.28 and a two-hundred day simple moving average of $19.67. Arcturus Therapeutics has a 1 year low of $14.30 and a 1 year high of $45.00. The company has a market cap of $463.78 million, a P/E ratio of -7.71 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the previous year, the business earned ($0.61) EPS.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Point72 DIFC Ltd acquired a new position in Arcturus Therapeutics during the 2nd quarter valued at about $188,000. Squarepoint Ops LLC acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at about $718,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at about $142,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at approximately $958,000. Finally, Millennium Management LLC boosted its stake in Arcturus Therapeutics by 250.1% in the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after purchasing an additional 396,505 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.